Jump to section
Enable Medicine's mission is to build and analyze highly detailed maps of human disease, facilitating novel drug target discovery, the identification of biomarkers of therapeutic response, and the development of optimal treatment strategies.
31% employee growth in 12 months
The biology of the human body holds the complex keys to discovering and developing new therapies and pharmaceuticals. However, the complexities of different areas of the body have different experts, fragmenting biological knowledge and stunting scientific development.
Enable Medicine provides a biological mapping platform for therapeutics discovery, collaborating with the world's leading researchers to index biological data. The company's platform then analyzes this data to construct highly detailed and searchable maps of complex diseases, making the exploration, navigation, and discovery of underlying biological rules possible.
While a rise in AI-driven precision medicine companies presents competition for Enable Medicine, the company stands out with its approach to sourcing biological data from leading researchers, using its platform to aggregate, analyze, and map this data. Through this approach, the company hopes to unify the knowledge of biological researchers, helping companies to discover new biological rules and develop new therapies and pharmaceuticals. Enable Medicine's $60 million in Series A will go a good way in strengthening its search engine.
Steph
Company Specialist at Welcome to the Jungle
Jan 2022
$60m
SERIES A
Aug 2020
$3.7m
EARLY VC
This company has top investors
Sunil Bodapati
(CEO)Experience as Forward Deployed Engineer in Business Development for Palantir Technologies from 2012 to 2014. Head of Product for Aurora Technologies from 2014 to 2016 and for Color Genomics from 2016 to 2018.
Aaron Mayer
(CSO)Complete a PhD in Bioengineering at Stanford University from 2014 to 2019.